SREBF1 regulates cholesterol and fatty acid synthesis, affecting the pharmacodynamics of fluvastatin, a cholesterol-lowering medication. Variations in SREBF1 may alter how fluvastatin modulates target gene expressions linked to cholesterol synthesis, thereby impacting the drug's effectiveness and necessitating possible adjustments in therapy for individuals with specific genetic variations.